BioPharm Brief: Dermatology, Neurology, and Oncology Updates

Jun 11, 12:31 AM
Headliner
Share
Subscribe

This week's BioPharm Brief covers the FDA's approval of every-eight-week maintenance dosing for lebrikizumab in atopic dermatitis, Sanofi's decision to halt a Phase 3 CIDP study of riliprubart after a futility analysis, and new mogamulizumab data being presented at WCCL 2026 in cutaneous T-cell lymphoma.

Share
Subscribe
Next
BioPharm Brief: RNAi, Obesity, and Diabetes Advances
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief